Drilldown: Medicines
Appearance
Medicines > classes
:
Benzodiazepine
or
Cathinone
or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) 
:
Benzodiazepine
or
Cathinone
or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) 
Use the filters below to narrow your results.
None (1) ·
3-MMC (1) ·
Alprazolam (1) ·
Bromazepam (1) ·
Butylone (1) ·
Cathinone (1) ·
Chlordiazepoxide (1) ·
Clobazam (1) ·
Clonazolam (1) ·
Clorazepate (1) ·
Diclazepam (1) ·
Ephylone (1) ·
Estazolam (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Flualprazolam (1) ·
Flubromazepam (1) ·
Flubromazolam (1) ·
Flunitrazepam (1) ·
Flunitrazolam (1) ·
Flurazepam (1) ·
Hexedrone (1) ·
Lormetazepam (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
Midazolam (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Nifoxipam (1) ·
Nitrazepam (1) ·
Oxazepam (1) ·
Pentedrone (1) ·
Pyrazolam (1) ·
Quazepam (1) ·
Temazepam (1) ·
Triazolam (1)
None (23) ·
Dalmane (1) ·
Doral (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Nuplazid (1) ·
Onfi (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Serax (1) ·
Tranxene (1) ·
Versed (1) ·
Xanax (1)
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
Showing below up to 38 results in range #1 to #38.

